Entero Therapeutics


Entero Therapeutics is a biopharmaceutical company focused on developing therapies for gastrointestinal diseases. Their mission is to develop innovative treatments to improve patient outcomes and quality of life, with ongoing research and clinical programs targeting gastrointestinal and infectious diseases.

Industries

biotechnology
health-care
pharmaceutical

Nr. of Employees

small (1-50)

Entero Therapeutics

Boca Raton, Florida, United States, North America


Products

Oral recombinant lipase formulated for enteric delivery

An orally administered, non-animal recombinant lipase formulated in enteric capsules intended to improve fat digestion and nutrient absorption in patients with exocrine pancreatic insufficiency.

Oral enzyme therapy for gluten peptide degradation

An orally delivered enzyme intended to degrade dietary gluten peptides in the GI tract to reduce antigenic exposure and associated symptoms.

Oral selective small-molecule GI receptor agonist

An orally administered small-molecule program targeting GI-specific receptors to modulate gastrointestinal motility for indications such as gastroparesis.


Services

Sponsor-led clinical development and trial management

Planning and operational execution of multi-center Phase 2 clinical trials, including protocol design, site activation, patient enrollment, safety oversight and endpoint management.

Clinical supply chain and packaging coordination

Management of clinical drug supply logistics, including selection and management of third‑party packaging and labeling vendors, QP release coordination and distribution to trial sites.

Regulatory support and IND interaction

Preparation of regulatory filings and engagement with health authorities to support clinical development strategy, IND submissions and agency meetings.

Expertise Areas

  • Clinical trial management for Phase 2 programs
  • Recombinant enzyme and non-animal biologics development
  • Gastrointestinal therapeutics and GI bioanalytics
  • Enteric oral formulation and targeted GI delivery
  • Show More (5)

Key Technologies

  • Recombinant enzyme therapeutics
  • Enteric / delayed-release oral capsule formulation
  • Oral non-systemic biologic delivery
  • Selective small-molecule GI receptor agonists
  • Show More (2)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.